CLOUDR (09955) announced its financial results for the year ended December 31, 2025. The company recorded revenue of RMB 1.62 billion and a gross profit of RMB 775 million. The gross profit margin for the period was 47.8%.

The significant improvement in the overall gross margin was attributed to an optimized revenue structure, with a strategic focus on high-margin subscription solutions and P2M solutions within both the in-hospital and out-of-hospital solution segments.

For the in-hospital solutions segment, the gross margin increased substantially to 48.0% for the year ended December 31, 2025, up from 25.2% for the previous year. This growth was primarily driven by a business restructuring that led to a higher revenue contribution from high-margin subscription solutions, such as precision marketing services provided to pharmaceutical companies, and P2M solutions for self-operated SKUs.

Regarding the out-of-hospital solutions segment, the gross margin also saw a significant rise to 47.2% for the year, compared to 23.1% for the prior year. This improvement was mainly due to a strategic business reorganization focused on cultivating high-quality, cash-flow-generating growth, which involved a deliberate reduction in low-margin pharmacy value-added solutions.